Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arianna Pagliaro

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Review of Anticancer Therapy|December 22, 2022
Current treatment approaches for brain metastases in <i>ALK</i>/<i>ROS1</i>/<i>NTRK</i>-positive non-small-cell lung cancerSabrina Rossi, Arianna Marinello, Arianna Pagliaro, et al.
Cancers|December 23, 2023
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?Sabrina Rossi, Arianna Pagliaro, Angelica Michelini, et al.
Cancer Treatment Reviews|July 4, 2024
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancerArianna Marinello, Marco Tagliamento, Arianna Pagliaro, et al.
Future Oncology (London, England)|March 6, 2024
Response to first-line pembrolizumab in metastatic <i>KRAS</i>-mutated non-small-cell lung cancerSabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Biomedicines|February 27, 2026
<i>PIK3CA</i> Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted PatientsSabrina Rossi, Arianna Pagliaro, Silvia Masini, et al.
Journal for Immunotherapy of Cancer|September 1, 2025
Regulatory polymorphisms of <i>MSH6</i>, <i>MSH2</i>, <i>FBXO11,</i> and <i>PPP1R21</i> genes affect survival of patients with immunotherapy-treated lung cancerMartina Esposito, Sara Noci, Francesca Minnai, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Review of Anticancer Therapy|December 22, 2022
Current treatment approaches for brain metastases in <i>ALK</i>/<i>ROS1</i>/<i>NTRK</i>-positive non-small-cell lung cancerSabrina Rossi, Arianna Marinello, Arianna Pagliaro, et al.
Cancers|December 23, 2023
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?Sabrina Rossi, Arianna Pagliaro, Angelica Michelini, et al.
Cancer Treatment Reviews|July 4, 2024
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancerArianna Marinello, Marco Tagliamento, Arianna Pagliaro, et al.
Future Oncology (London, England)|March 6, 2024
Response to first-line pembrolizumab in metastatic <i>KRAS</i>-mutated non-small-cell lung cancerSabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.
Biomedicines|February 27, 2026
<i>PIK3CA</i> Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted PatientsSabrina Rossi, Arianna Pagliaro, Silvia Masini, et al.
Journal for Immunotherapy of Cancer|September 1, 2025
Regulatory polymorphisms of <i>MSH6</i>, <i>MSH2</i>, <i>FBXO11,</i> and <i>PPP1R21</i> genes affect survival of patients with immunotherapy-treated lung cancerMartina Esposito, Sara Noci, Francesca Minnai, et al.
The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.
Pageof 1